Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drugs In Development, 2021

June 2021 | 176 pages | ID: BF34485EB7ADEN
Global Markets Direct

Abstracts

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drugs In Development, 2021

SUMMARY

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription.

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 43 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 7, 17 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Genito Urinary System And Sex Hormones and Immunology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Ovarian Cancer, Myelofibrosis, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Pancreatic Cancer, Small-Cell Lung Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Lung Cancer, Lymphoma, Non-Hodgkin Lymphoma, Atopic Dermatitis (Atopic Eczema), Breast Cancer, Colon Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Hematological Tumor, Leukemia, Myeloproliferative Disorders, Neuroblastoma, Non-Small Cell Lung Cancer, Peritoneal Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Advanced Malignancy, B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Cervical Cancer, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Cognitive Disorders, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Coronavirus Disease 2019 (COVID-19), Fabry Disease, Facioscapulohumeral Muscular Dystrophy (FSHD), Fibrosis, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Primary Mediastinal B-Cell Lymphoma, Psoriasis, Pulmonary Arterial Hypertension, Renal Cell Carcinoma, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma), Unspecified B-Cell Lymphomas, Uterine Cancer, Uveal Melanoma, Vaginal Cancer, Vascular Dementias and Vulvar Cancer.

The latest report Bromodomain Containing Protein 4 - Drugs In Development, 2021, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
• The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
• The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AbbVie Inc, 2021
Pipeline by Amgen Inc, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by Boehringer Ingelheim International GmbH, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by Bromodomain Pharmaceuticals Inc, 2021
Pipeline by C4 Therapeutics Inc, 2021
Pipeline by Checkpoint Therapeutics Inc, 2021
Pipeline by Constellation Pharmaceuticals Inc, 2021
Pipeline by ConverGene LLC, 2021
Pipeline by CSPC Pharmaceutical Group Ltd, 2021
Pipeline by Epigene Therapeutics Inc, 2021
Pipeline by Kainos Medicine Inc, 2021
Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2021
Pipeline by Nuvation Bio Inc, 2021
Pipeline by OHM Oncology, 2021
Pipeline by Phio Pharmaceuticals Corp, 2021
Pipeline by Plexxikon Inc, 2021
Pipeline by Red Glead Discovery AB, 2021
Pipeline by Resverlogix Corp, 2021
Pipeline by Roivant Sciences Ltd, 2021
Pipeline by SignalRx Pharmaceuticals Inc, 2021
Pipeline by Zenith Epigenetics Ltd, 2021
Dormant Products, 2021
Discontinued Products, 2021
Discontinued Products, 2021 (Contd..1)

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021